Implantica AG (IMP-A-SDB.ST)
SEK 37.65
(2.45%)
SEK 37.65
(2.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.9 Million EUR | 13.54% |
| 2022 | 4.32 Million EUR | 34.41% |
| 2021 | 3.21 Million EUR | 85.46% |
| 2020 | 1.73 Million EUR | -78.73% |
| 2019 | 8.14 Million EUR | 169.73% |
| 2018 | 3.02 Million EUR | 4.31% |
| 2017 | 2.89 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.1 Million EUR | 4.08% |
| 2024 Q2 | 4.29 Million EUR | -15.87% |
| 2023 Q1 | 4.25 Million EUR | -1.53% |
| 2023 Q3 | 5.1 Million EUR | 11.56% |
| 2023 FY | 4.9 Million EUR | 13.54% |
| 2023 Q4 | 4.9 Million EUR | -3.96% |
| 2023 Q2 | 4.57 Million EUR | 7.62% |
| 2022 Q1 | 2.99 Million EUR | -6.91% |
| 2022 Q2 | 3.49 Million EUR | 16.81% |
| 2022 Q3 | 4.18 Million EUR | 19.77% |
| 2022 Q4 | 4.32 Million EUR | 3.2% |
| 2022 FY | 4.32 Million EUR | 34.41% |
| 2021 Q3 | 3.31 Million EUR | 14.09% |
| 2021 Q1 | 1.83 Million EUR | 5.65% |
| 2021 Q2 | 2.9 Million EUR | 58.55% |
| 2021 FY | 3.21 Million EUR | 85.46% |
| 2021 Q4 | 3.21 Million EUR | -2.96% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q3 | 7.1 Million EUR | -30.76% |
| 2020 Q2 | 10.25 Million EUR | 0.0% |
| 2020 FY | 1.73 Million EUR | -78.73% |
| 2020 Q4 | 1.73 Million EUR | -75.59% |
| 2019 FY | 8.14 Million EUR | 169.73% |
| 2019 Q4 | 8.14 Million EUR | 0.0% |
| 2018 FY | 3.02 Million EUR | 4.31% |
| 2017 FY | 2.89 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | 55.401% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.817% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.817% |
| Arcoma AB | 33.3 Million SEK | 85.272% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 98.512% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.85% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 98.248% |
| CellaVision AB (publ) | 212.32 Million SEK | 97.69% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | 65.45% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | 28.592% |
| C-Rad AB (publ) | 122.4 Million SEK | 95.993% |
| Duearity AB (publ) | 17.53 Million SEK | 72.019% |
| Dignitana AB (publ) | 37.56 Million SEK | 86.943% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 75.227% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.98% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 76.19% |
| Iconovo AB (publ) | 14.55 Million SEK | 66.298% |
| Integrum AB (publ) | 22.07 Million SEK | 77.778% |
| Luxbright AB (publ) | 7 Million SEK | 29.93% |
| Mentice AB (publ) | 163.55 Million SEK | 97.001% |
| OssDsign AB (publ) | 105.25 Million SEK | 95.34% |
| Paxman AB (publ) | 44.5 Million SEK | 88.98% |
| Promimic AB (publ) | 16.15 Million SEK | 69.64% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 92.11% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 76.948% |
| ScandiDos AB (publ) | 37.18 Million SEK | 86.81% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.701% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 88.868% |
| Senzime AB (publ) | 58.06 Million SEK | 91.553% |
| SpectraCure AB (publ) | 14.97 Million SEK | 67.245% |
| Stille AB | 172.64 Million SEK | 97.159% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.866% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 98.042% |